1912 related articles for article (PubMed ID: 19359080)
1. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
Heinz J; Kropf S; Luley C; Dierkes J
Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
[TBL] [Abstract][Full Text] [Related]
2. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial.
Heinz J; Kropf S; Domröse U; Westphal S; Borucki K; Luley C; Neumann KH; Dierkes J
Circulation; 2010 Mar; 121(12):1432-8. PubMed ID: 20231532
[TBL] [Abstract][Full Text] [Related]
3. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
[TBL] [Abstract][Full Text] [Related]
4. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.
Clarke R; Armitage J
Semin Thromb Hemost; 2000; 26(3):341-8. PubMed ID: 11011852
[TBL] [Abstract][Full Text] [Related]
5. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
Gonin JM; Nguyen H; Gonin R; Sarna A; Michels A; Masri-Imad F; Bommareddy G; Chassaing C; Wainer I; Loya A; Cary D; Barker LF; Assefi A; Greenspan R; Mahoney D; Wilcox CS
J Nephrol; 2003; 16(4):522-34. PubMed ID: 14696754
[TBL] [Abstract][Full Text] [Related]
6. Elevated homocysteine levels in patients with end-stage renal disease.
Nair AP; Nemirovsky D; Kim M; Geer EB; Farkouh ME; Winston J; Halperin JL; Robbins MJ
Mt Sinai J Med; 2005 Nov; 72(6):365-73. PubMed ID: 16358160
[TBL] [Abstract][Full Text] [Related]
7. Homocysteine and renal disease.
van Guldener C; Robinson K
Semin Thromb Hemost; 2000; 26(3):313-24. PubMed ID: 11011849
[TBL] [Abstract][Full Text] [Related]
8. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease.
Dierkes J; Domröse U; Ambrosch A; Bosselmann HP; Neumann KH; Luley C
Clin Nephrol; 1999 Feb; 51(2):108-15. PubMed ID: 10069646
[TBL] [Abstract][Full Text] [Related]
9. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease.
Buccianti G; Baragetti I; Bamonti F; Furiani S; Dorighet V; Patrosso C
J Nephrol; 2004; 17(3):405-10. PubMed ID: 15365961
[TBL] [Abstract][Full Text] [Related]
10. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.
Jamison RL; Hartigan P; Kaufman JS; Goldfarb DS; Warren SR; Guarino PD; Gaziano JM;
JAMA; 2007 Sep; 298(10):1163-70. PubMed ID: 17848650
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels.
Miller ER; Juraschek S; Pastor-Barriuso R; Bazzano LA; Appel LJ; Guallar E
Am J Cardiol; 2010 Aug; 106(4):517-27. PubMed ID: 20691310
[TBL] [Abstract][Full Text] [Related]
12. Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients.
Deicher R; Ziai F; Bieglmayer C; Schillinger M; Hörl WH
J Am Soc Nephrol; 2005 Jun; 16(6):1811-8. PubMed ID: 15814831
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance.
Mudge DW; Rogers R; Hollett P; Law B; Reiger K; Petrie JJ; Price L; Johnson DW; Campbell SB; Isbel NM; Sullivan M; Hawley CM
Nephrol Dial Transplant; 2005 Oct; 20(10):2178-85. PubMed ID: 16030045
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial.
Bostom AG; Carpenter MA; Kusek JW; Hunsicker LG; Pfeffer MA; Levey AS; Jacques PF; McKenney J;
Am Heart J; 2006 Sep; 152(3):448.e1-7. PubMed ID: 16923411
[TBL] [Abstract][Full Text] [Related]
15. Observational study on markers of cardiovascular risk in renal patient: conventional hemodialysis vs. haemofiltration online.
Melero-Rubio E; Párraga-Díaz M; Gómez-Sánchez MP; Pellicer-Villaescusa S; Merchán-Mayado E
J Ren Care; 2009 Dec; 35(4):201-4. PubMed ID: 19909413
[TBL] [Abstract][Full Text] [Related]
16. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
Lovcić V; Kes P; Zeljko R; Kusec V
Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
[TBL] [Abstract][Full Text] [Related]
17. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events.
Vianna AC; Mocelin AJ; Matsuo T; Morais-Filho D; Largura A; Delfino VA; Soares AE; Matni AM
Hemodial Int; 2007 Apr; 11(2):210-6. PubMed ID: 17403173
[TBL] [Abstract][Full Text] [Related]
18. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients.
Righetti M; Serbelloni P; Milani S; Ferrario G
Blood Purif; 2006; 24(4):379-86. PubMed ID: 16755160
[TBL] [Abstract][Full Text] [Related]
19. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study.
Mann JF; Sheridan P; McQueen MJ; Held C; Arnold JM; Fodor G; Yusuf S; Lonn EM;
Nephrol Dial Transplant; 2008 Feb; 23(2):645-53. PubMed ID: 18003666
[TBL] [Abstract][Full Text] [Related]
20. The effect of long-term intravenous high dose B-complex vitamins with or without folic acid on serum homocysteine in hemodialysis patients.
Sombolos K; Fragia T; Natse T; Bartholomatos G; Karagianni A; Katsaris G; Christidou F; Bamichas G; Stangou M; Papagalanis N
J Nephrol; 2002; 15(6):671-5. PubMed ID: 12495282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
